HER2DX test to guide treatment for early HER2+ breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether a new test (HER2DX) can help doctors choose the best treatment combination for HER2-positive breast cancer before surgery. It's for people whose cancer hasn't spread and who haven't started therapy yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your breast cancer must be HER2-positive (a protein that helps cancer grow).
- The cancer must be early-stage (not spread to distant organs) and you haven't had any treatment for it yet.
- You need to be in fairly good health to handle chemotherapy and targeted therapy, and your heart function must be normal.
- You must have a tumor sample available to run a special test called HER2DX.
- If you could become pregnant, you must use very effective birth control during treatment and for several months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.
This study tests a tool called HER2DX to help doctors choose the best treatment for early stage HER2 positive breast cancer. It may help tailor therapy before or after surgery.
This trial is studying whether a blood test can help doctors choose the right treatment for women with a certain type of breast cancer (HER2-low). It focuses on a common chemotherapy drug (docetaxel) and how well it works based on the blood test results.
This trial tests two study drugs, HLX22 and HLX87, together for people with HER2-positive breast cancer that has spread or come back. It may be an option if you haven't yet had chemotherapy or HER2-targeted therapy for advanced disease.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.